Recently, Jinyu Medical (603882) and the neurology team of Shanghai Ruijin Hospital conducted a study on the clinical phenotype of patients with anti-IgLON5 encephalitis.
The diagnosis of such encephalitis diseases relies on accurate and reliable antibody detection technology, and Jinyu Medicine has cooperated with hospitals to collect cases and discover a variety of special disease phenotypes that have not been reported internationally before. Finally, the research results on the clinical phenotype of patients with anti-IgLON5 encephalitis were published online in EuropeanJournalofNeurology (IF=6.089), which is conducive to better understanding and treatment of the disease by domestic and foreign medical institutions.
The expansion of market demand promotes the high-quality development of the industry
In recent years, under the comprehensive influence of factors such as the promotion of national policy dividends, the expansion of people's medical and health needs, and the continuous iterative application of new diagnosis and treatment technologies, the domestic third-party medical testing industry has accelerated its development, and the industry penetration rate has accelerated, ushering in a new development trend.
According to statistics, in 2018, the scale of China's third-party medical testing market was about 12.5 billion yuan, and it continued to maintain a good development trend. With the support of national policies, the scale is expected to exceed 80 billion in 2024, with an annual compound growth rate of about 35%, accounting for about 7%-9% of the medical laboratory market, and the industry is developing rapidly.
As a pioneer of third-party medical examination in China, Jinyu Medical has been committed to the clinical innovation and transformation in the field of neurology. The company's main business is to provide outsourcing and scientific research and technical services for more than 2,800 inspection projects in six categories, including physical and chemical mass spectrometry, genomic examination, pathological diagnosis, biochemical luminescence testing, immunology testing, and other comprehensive tests, for more than 23,000 medical institutions nationwide.
At the same time, Jinyu Medical has implemented a diversified development strategy, and has gradually expanded medical examination to the fields of health examination, sales of diagnostic products and cold chain logistics services. From the perspective of revenue structure, in 2020, Jinyu Medical Diagnosis Services, Health Examination, Sales diagnostic products and cold chain logistics services achieved operating income of 7.87 billion yuan, 0.34 billion yuan, 156 million yuan and 0.27 billion yuan respectively; in the first half of 2021, the company's revenue also exceeded 5.4 billion yuan, an increase of 57% year-on-year, and the company's performance increased steadily.
In addition, Golden Mile Medicine has established 38 central laboratories across the country (including Hong Kong, China), and extensively established regional central laboratories and rapid response laboratories, and the service network covers the regions where more than 90% of the country's population is located. At the same time, the company has obtained 40 domestic and foreign certification certificates, the number of third-party independent medical laboratories in the industry first, the test results for more than 70 countries and regions around the world recognized, has become the domestic third-party medical testing industry business scale of the largest scale, the widest service network coverage, the most complete testing projects and technology platform of the market leader enterprises.
Strong scientific and technological innovation and research and development capabilities
Jinyu Medicine has the world's leading ultra-micro pathology diagnosis center for kidney disease, the respiratory virus diagnosis research center docked with the national platform, and has been identified as a national high-tech enterprise, a national genetic testing technology application demonstration center, a national intellectual property demonstration enterprise, a national small and medium-sized enterprise public technical service demonstration platform, etc., and has been approved to establish a national and local joint engineering laboratory for medical testing technology and services, a national postdoctoral research workstation, a Guangdong provincial academician workstation, a guangdong provincial key laboratory of enterprises, etc. Provincial and ministerial R&D institutions and R&D platforms.
Jinyu Medicine has always benchmarked against international cutting-edge technologies and advanced peers, extensively integrated domestic and foreign resources, and created an international leading service clinical and disease innovation capability. The company has established in-depth strategic cooperative relations with Academician Zhong Nanshan, Academician Hou Fanfan, Academician Zeng Yitao, Academician Xie Xiaoliang, Academician Zhang Xuexue, Academician Chen Yeguang and Academician Lu Yuming, the founder of the global "NIPT" (non-invasive prenatal) technology, and has achieved a series of results.
At the same time, it has carried out in-depth cooperation with overseas and domestic universities, research institutions and enterprises such as City University of Hong Kong, Peking Union Medical College Hospital, National Center for Disease Control and Prevention, Huawei, Tencent and Gilead Sciences, etc., and has made multi-point efforts and rich achievements in clinical diagnostic services, new technology research and development, big data research, pathological artificial intelligence assisted diagnosis, precision medicine, discipline capacity building, and talent training.
Jinyu Medicine has built a three-level technological innovation system, through independent innovation, collaborative innovation, open innovation, the formation of a perfect and comprehensive inspection and diagnosis technology system in the industry, covering 72 types of testing technology, of which 32 are domestic leading technologies, 9 categories reach the international advanced level.
Jinyu Medicine has also built a number of high-tech testing centers such as clinical genome testing center, clinical mass spectrometry testing center, clinical blood disease diagnosis center, pathology screening and diagnosis center, infectious disease testing center, etc., and built a complete laboratory testing technology platform in the industry, covering mainstream technology fields from conventional to high-end, and can currently provide more than 2,800 test items.
In the first half of the year, Jinyu Medical successfully promoted digital transformation, the digital science team was formally established, the digital project was gradually launched, and 7 projects were completed within the company in terms of business digitization, digital business, technology and data foundation. The company accelerated the promotion of "double creation" activities, internally registered 458 "double creation" groups, registered 537 topics, and the number of participants reached 1529 people. The company's "Improving the Nucleic Acid Detection Capacity of Guangzhou Jinyu Novel Coronavirus" was awarded the ICQCC Recommended Winning Grade Achievement, successfully advanced and invited to participate in the 2021 International Competition.
Multi-level coverage of the market and logistics network advantages
As an independent medical laboratory with the largest number of chain laboratories, the widest coverage area and the largest number of customers in China, Jinyu Medical has a laboratory network and logistics network throughout the country, with more than 2,500 logistics outlets, enabling the company to provide safe, fast, convenient and diversified medical testing and pathological diagnosis services for more than 23,000 customers of different types in various places.
At present, in response to the national hierarchical diagnosis and treatment and the call of "90% of serious diseases do not leave the county", Jinyu Medical has cooperated with more than 600 medical institutions to build an inspection and pathological diagnosis center.
In order to further enhance the experience of inspection and pathological diagnosis services of cooperative medical institutions, Jinyu Medical conducts full-process analysis from the aspects of demand introduction, logistics support, inspection support and diversified services, value-added services, etc., strengthens basic support through logistics informatization, equipment lean, operation standardization, service diversification and other means, and combines the professional management and control system of the laboratory to continuously provide customers with clinical diagnosis and treatment information and solutions with advanced technology, complete projects, reliable results and controllable processes. Meet the needs of medical institutions at all levels in the region.
At the same time, Jinyu Medical vigorously integrates the service resources of medical institutions at all levels in the region, effectively sinks high-quality resources to the vast grass-roots medical institutions such as cities, counties, townships and communities, and actively responds to the call of the state to revitalize the countryside with practical actions.
Recently, at the China Quality (Hangzhou) Conference, Jinyu Medicine's five-dimensional quality management model of "health sentinel" with quality as life won the nomination award of China Quality Award, becoming the first batch of enterprises in China's third-party medical inspection industry to receive this honor. Liang Yaoming, chairman and CEO of the Group, said that Jinyu Medical will continue to promote the professional values and social responsibilities of "health sentinels" to empower clinical, help public health, and protect people's health, help build a healthy China and build a quality power, and promote the Chinese medical inspection brand to go international.
This article originated from Lanfu Finance